Centessa Pharmaceuticals plc
CNTA
$16.08
-$0.73-4.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 118.88% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 118.88% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 118.88% | -- | -- | -- | -- |
| SG&A Expenses | -2.76% | -5.43% | -10.45% | -11.74% | -10.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.45% | 12.87% | -5.18% | -12.98% | -20.48% |
| Operating Income | -23.50% | -17.38% | 9.03% | 16.66% | 23.77% |
| Income Before Tax | -34.47% | -32.23% | 14.09% | 19.81% | 23.01% |
| Income Tax Expenses | 114.89% | 111.35% | 110.94% | 97.95% | -16,734.67% |
| Earnings from Continuing Operations | -61.72% | -56.04% | -2.44% | 8.86% | 34.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.72% | -56.04% | -2.44% | 8.86% | 34.84% |
| EBIT | -23.50% | -17.38% | 9.03% | 16.66% | 23.77% |
| EBITDA | -23.60% | -17.30% | 9.20% | 16.85% | 23.97% |
| EPS Basic | -27.31% | -26.63% | 7.78% | 14.59% | 36.92% |
| Normalized Basic EPS | 7.16% | 4.56% | 21.75% | 23.32% | 25.44% |
| EPS Diluted | -27.31% | -26.63% | 7.78% | 14.59% | 36.92% |
| Normalized Diluted EPS | 7.16% | 4.56% | 21.75% | 23.32% | 25.44% |
| Average Basic Shares Outstanding | 25.98% | 18.98% | 11.07% | 6.57% | 3.08% |
| Average Diluted Shares Outstanding | 25.98% | 18.98% | 11.07% | 6.57% | 3.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |